Literature DB >> 11333903

Enhancement of adenovirus vector entry into CD70-positive B-cell Lines by using a bispecific CD70-adenovirus fiber antibody.

B F Israel1, R J Pickles, D M Segal, R D Gerard, S C Kenney.   

Abstract

Although many recombinant adenovirus vectors (rAd) have been developed, especially by using group C adenoviruses, to transfer and express genes, such rAd do not readily infect B-cell lines due to the lack of the coxsackievirus-adenovirus receptor. Bispecific antibodies have been used in different cell systems to facilitate entry of rAd into otherwise nonpermissive cells. Bispecific antibody is synthesized by covalently linking two monoclonal antibodies with distinct specificities. It has been shown that lymphoproliferative tumors commonly express the cell surface protein CD70, while this receptor is normally expressed on only a small subset of highly activated B cells and T cells. We therefore investigated whether a bispecific antibody with specificities for the adenovirus fiber protein and CD70 can facilitate rAd entry and subsequent expression of rAd-encoded genes in CD70-positive B cells. We found high CD70 expression on Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs), as well as some, but not all, Burkitt lymphoma (BL) lines. We show here that rAd encoding green fluorescent protein (Ad-GFP) infects EBV-transformed LCLs and a CD70-positive BL line 10- to 20-fold more efficiently in the presence of the CD70-fiber bispecific antibody. In contrast, the bispecific antibody does not enhance Ad-GFP infection in CD70-deficient BL cells. Using the CD70-fiber bispecific antibody, we increased the ability of rAd vectors encoding the EBV immediate-early proteins BZLF1 and BRLF1 to induce the lytic form of EBV infection in LCLs. These results indicate that the CD70-fiber bispecific antibody can enhance rAd infection of CD70-positive B cells and suggest the use of this vector to explore EBV-positive LCLs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11333903      PMCID: PMC114927          DOI: 10.1128/JVI.75.11.5215-5221.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes.

Authors:  S Huang; D Stupack; P Mathias; Y Wang; G Nemerow
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

2.  Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies.

Authors:  T J Wickham; D M Segal; P W Roelvink; M E Carrion; A Lizonova; G M Lee; I Kovesdi
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

3.  Targeted adenovirus-mediated gene delivery to T cells via CD3.

Authors:  T J Wickham; G M Lee; J A Titus; G Sconocchia; T Bakács; I Kovesdi; D M Segal
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein.

Authors:  S C Stevenson; M Rollence; J Marshall-Neff; A McClelland
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

Review 5.  Pathophysiology of Hodgkin's disease: functional and molecular aspects.

Authors:  H J Gruss; M E Kadin
Journal:  Baillieres Clin Haematol       Date:  1996-09

6.  Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells.

Authors:  S Huang; T Kamata; Y Takada; Z M Ruggeri; G R Nemerow
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

7.  HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses.

Authors:  R P Tomko; R Xu; L Philipson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

8.  B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules.

Authors:  L Trentin; R Zambello; R Sancetta; M Facco; A Cerutti; A Perin; M Siviero; U Basso; M Bortolin; F Adami; C Agostini; G Semenzato
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

Review 9.  CD27-CD70 interaction: unravelling its implication in normal and neoplastic B-cell growth.

Authors:  S M Lens; R de Jong; R Q Hintzen; G Koopman; R A van Lier; R H van Oers
Journal:  Leuk Lymphoma       Date:  1995-06

10.  Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism.

Authors:  S Zalani; E Holley-Guthrie; S Kenney
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

View more
  5 in total

1.  Resistance of canine lymphoma cells to adenoviral infection due to reduced cell surface RGD binding integrins.

Authors:  Ann Marie O'Neill; Annette N Smith; Elizabeth A Spangler; Elizabeth M Whitley; Stephanie E Schleis; Richard C Bird; David T Curiel; Erin E Thacker; Bruce F Smith
Journal:  Cancer Biol Ther       Date:  2011-04-01       Impact factor: 4.742

2.  Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors.

Authors:  Wen-hai Feng; Eva Westphal; Amy Mauser; Nancy Raab-Traub; Margaret L Gulley; Pierre Busson; Shannon C Kenney
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.

Authors:  Wen-hai Feng; Gregory Hong; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

4.  Retargeting adenoviral vectors to improve gene transfer into tumors.

Authors:  R T Hogg; P Thorpe; R D Gerard
Journal:  Cancer Gene Ther       Date:  2010-12-24       Impact factor: 5.987

5.  Analysis of the cross-talk of Epstein-Barr virus-infected B cells with T cells in the marmoset.

Authors:  Jordon Dunham; Nikki van Driel; Bart Jl Eggen; Chaitali Paul; Bert A 't Hart; Jon D Laman; Yolanda S Kap
Journal:  Clin Transl Immunology       Date:  2017-02-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.